德?tīng)査儺惗局暾谌蛩僚?。這種高傳染性和快速蔓延的冠狀病毒突變(它可能反過(guò)來(lái)產(chǎn)生更多的變體)正在重創(chuàng)歐洲和印度,并在美國(guó)的新感染病例中占據(jù)越來(lái)越大的份額。
應(yīng)對(duì)新冠病毒始終需要采取多管齊下的策略,包括病毒檢測(cè)、追蹤接觸者、保持社交距離、戴口罩,并最終開(kāi)展一場(chǎng)前所未有的疫苗接種運(yùn)動(dòng)。在免疫方面,初步證據(jù)表明,輝瑞(Pfizer)、阿斯利康(AstraZeneca)和Moderna疫苗在預(yù)防德?tīng)査儺惗局旮腥菊甙l(fā)展成為重癥、住院治療乃至死亡方面都非常有效。Moderna疫苗甚至有望幫助接種者獲得足以抵御這種毒株的抗體。但市面上常見(jiàn)的新冠病毒檢測(cè)手段能夠檢測(cè)到德?tīng)査儺惗局陠幔?/p>
簡(jiǎn)單來(lái)說(shuō):不一定。盡管德?tīng)査儺惗局辏ㄒ脖环Q(chēng)為B.1.617.2)可能是新冠病毒的后代,但它帶有獨(dú)特的生物標(biāo)記。就學(xué)術(shù)機(jī)構(gòu),以及雅培(Abbott)和羅氏(Roche)等醫(yī)療巨頭提供的數(shù)十種商業(yè)新冠病毒測(cè)試手段而言,有一些可能無(wú)法檢測(cè)到這種毒株。
對(duì)德?tīng)査儺惗局甑臋z測(cè),通常需要在更精確的水平上進(jìn)行,而這通常涉及到聚合酶鏈?zhǔn)椒磻?yīng)(PCR)檢測(cè)平臺(tái)。該平臺(tái)往往可以更加精確、更加敏銳地發(fā)現(xiàn)冠狀病毒內(nèi)的基因變異。但這種水平的測(cè)試也比快速反應(yīng)測(cè)試需要更多的時(shí)間,后者可能在半小時(shí)內(nèi)出結(jié)果,盡管它會(huì)錯(cuò)過(guò)一些生物學(xué)細(xì)節(jié)。這些快速診斷方法或許能夠檢測(cè)出你是否感染了新冠病毒,但不一定可以檢測(cè)出你感染的是德?tīng)査儺惗局辍?/p>
例如,南卡羅來(lái)納州的公共衛(wèi)生部門(mén)并沒(méi)有定期篩查德?tīng)査儺惗局辍_@意味著,只有少數(shù)與德?tīng)査儺惗局暧嘘P(guān)的病例被明確識(shí)別,盡管考慮到這種毒株在美國(guó),特別是在南部和中西部傳播得如此之快,真實(shí)的感染病例可能要高得多。
該州的公共衛(wèi)生部門(mén)解釋說(shuō),最初的新冠病毒測(cè)試將不得不接受額外的篩查,這需要對(duì)患者的樣本進(jìn)行更復(fù)雜的基因組測(cè)序,以確定它是不是德?tīng)査儺惗局瓴±@個(gè)過(guò)程往往受制于幾家正在進(jìn)行篩查的私人、州和聯(lián)邦實(shí)驗(yàn)室的檢測(cè)能力。
與此同時(shí),一些公司已經(jīng)著手開(kāi)發(fā)快速檢測(cè)方法,希望在不進(jìn)行花里胡哨的聚合酶鏈?zhǔn)椒磻?yīng)測(cè)試的情況下,檢測(cè)到德?tīng)査儺惗局?。一家名為Avacta的公司聲稱(chēng),其抗原測(cè)試能夠檢測(cè)到該變體。在飽受德?tīng)査儺惗局甏驌舻挠?guó),一些公司正在開(kāi)發(fā)更復(fù)雜的聚合酶鏈?zhǔn)椒磻?yīng)技術(shù)來(lái)監(jiān)測(cè)這種毒株。
不管新冠病毒檢測(cè)能否顯示你感染了一種或另一種毒株,臨床研究的總體信息都是明確的:接種疫苗是預(yù)防重癥和保護(hù)他人的最佳方式,無(wú)論新冠病毒采用何種新化身。(財(cái)富中文網(wǎng))
譯者:任文科
德?tīng)査儺惗局暾谌蛩僚?。這種高傳染性和快速蔓延的冠狀病毒突變(它可能反過(guò)來(lái)產(chǎn)生更多的變體)正在重創(chuàng)歐洲和印度,并在美國(guó)的新感染病例中占據(jù)越來(lái)越大的份額。
應(yīng)對(duì)新冠病毒始終需要采取多管齊下的策略,包括病毒檢測(cè)、追蹤接觸者、保持社交距離、戴口罩,并最終開(kāi)展一場(chǎng)前所未有的疫苗接種運(yùn)動(dòng)。在免疫方面,初步證據(jù)表明,輝瑞(Pfizer)、阿斯利康(AstraZeneca)和Moderna疫苗在預(yù)防德?tīng)査儺惗局旮腥菊甙l(fā)展成為重癥、住院治療乃至死亡方面都非常有效。Moderna疫苗甚至有望幫助接種者獲得足以抵御這種毒株的抗體。但市面上常見(jiàn)的新冠病毒檢測(cè)手段能夠檢測(cè)到德?tīng)査儺惗局陠幔?/p>
簡(jiǎn)單來(lái)說(shuō):不一定。盡管德?tīng)査儺惗局辏ㄒ脖环Q(chēng)為B.1.617.2)可能是新冠病毒的后代,但它帶有獨(dú)特的生物標(biāo)記。就學(xué)術(shù)機(jī)構(gòu),以及雅培(Abbott)和羅氏(Roche)等醫(yī)療巨頭提供的數(shù)十種商業(yè)新冠病毒測(cè)試手段而言,有一些可能無(wú)法檢測(cè)到這種毒株。
對(duì)德?tīng)査儺惗局甑臋z測(cè),通常需要在更精確的水平上進(jìn)行,而這通常涉及到聚合酶鏈?zhǔn)椒磻?yīng)(PCR)檢測(cè)平臺(tái)。該平臺(tái)往往可以更加精確、更加敏銳地發(fā)現(xiàn)冠狀病毒內(nèi)的基因變異。但這種水平的測(cè)試也比快速反應(yīng)測(cè)試需要更多的時(shí)間,后者可能在半小時(shí)內(nèi)出結(jié)果,盡管它會(huì)錯(cuò)過(guò)一些生物學(xué)細(xì)節(jié)。這些快速診斷方法或許能夠檢測(cè)出你是否感染了新冠病毒,但不一定可以檢測(cè)出你感染的是德?tīng)査儺惗局辍?/p>
例如,南卡羅來(lái)納州的公共衛(wèi)生部門(mén)并沒(méi)有定期篩查德?tīng)査儺惗局?。這意味著,只有少數(shù)與德?tīng)査儺惗局暧嘘P(guān)的病例被明確識(shí)別,盡管考慮到這種毒株在美國(guó),特別是在南部和中西部傳播得如此之快,真實(shí)的感染病例可能要高得多。
該州的公共衛(wèi)生部門(mén)解釋說(shuō),最初的新冠病毒測(cè)試將不得不接受額外的篩查,這需要對(duì)患者的樣本進(jìn)行更復(fù)雜的基因組測(cè)序,以確定它是不是德?tīng)査儺惗局瓴±?,而這個(gè)過(guò)程往往受制于幾家正在進(jìn)行篩查的私人、州和聯(lián)邦實(shí)驗(yàn)室的檢測(cè)能力。
與此同時(shí),一些公司已經(jīng)著手開(kāi)發(fā)快速檢測(cè)方法,希望在不進(jìn)行花里胡哨的聚合酶鏈?zhǔn)椒磻?yīng)測(cè)試的情況下,檢測(cè)到德?tīng)査儺惗局辍R患颐麨锳vacta的公司聲稱(chēng),其抗原測(cè)試能夠檢測(cè)到該變體。在飽受德?tīng)査儺惗局甏驌舻挠?guó),一些公司正在開(kāi)發(fā)更復(fù)雜的聚合酶鏈?zhǔn)椒磻?yīng)技術(shù)來(lái)監(jiān)測(cè)這種毒株。
不管新冠病毒檢測(cè)能否顯示你感染了一種或另一種毒株,臨床研究的總體信息都是明確的:接種疫苗是預(yù)防重癥和保護(hù)他人的最佳方式,無(wú)論新冠病毒采用何種新化身。(財(cái)富中文網(wǎng))
譯者:任文科
The Delta variant is wreaking havoc across the globe. The highly transmissible and rapidly spreading coronavirus mutation (which may in turn be creating even more variants) is battering Europe and India and contributing to a growing share of new COVID cases in the U.S.
Tackling COVID has always necessitated a multipronged strategy involving coronavirus testing, contact tracing, distancing, and masking procedures, and ultimately an unprecedented vaccination campaign. On the immunization front, initial evidence suggests that Pfizer’s, AstraZeneca’s, and Moderna’s COVID vaccines are all remarkably effective in preventing serious illness, hospitalization, and death among patients who contract the Delta variant. Moderna’s shot has even shown promise in producing antibodies that protect against this strain. But can the actual COVID tests on the market detect the Delta variant?
To put it simply: not always. While the Delta variant (otherwise known as B.1.617.2) may be the pathogenic offspring of the novel coronavirus, it carries distinctive biological markers that some among the dozens of commercially available COVID tests from academic institutes and medical giants such as Abbott and Roche may not be able to sense.
Testing for the Delta variant usually has to be done on a more precise level involving polymerase chain reaction (PCR) testing platforms, which tend to be more accurate and sensitive to genetic variations within the coronavirus. But that level of testing also takes more time than a rapid response test which may return results within a half-hour but miss out on some of the biological details. Those faster diagnostics may be able to sense whether or not you’re generally infected with COVID, but not necessarily whether it’s the Delta strain specifically that’s afflicting you.
For instance, in South Carolina, Delta variants aren’t regularly screened for by the state’s public health department. That means that just a handful of Delta-variant linked cases have been specifically identified even though the true number is likely much higher given how quickly this strain is spreading in the U.S., particularly in the South and the Midwest.
An initial COVID test would then have to receive additional screening that involves more intricate genomic sequencing of a patient’s sample in order to home in on whether or not it’s a Delta variant case, and that process is reliant on a mishmash of private, state, and federal laboratories that are carrying out the screening, according to South Carolina’s public health department.
In the meantime, companies are already going to work on creating rapid tests which can detect the Delta variant without requiring all the bells and whistles of an intensive PCR test. One firm, Avacta, says its own antigen test can detect the variant. In the U.K., which has been hit hard by the Delta variant, more sophisticated PCR technology is being developed in order to keep tabs on the strain.
Regardless of whether a test can tell you if you have one COVID strain or another, the overall message from clinical studies is clear: Getting vaccinated is the best way to prevent serious illness and to protect others, no matter what new avatar the coronavirus takes.